Migraine treatment might just be a huge thing this 2017 after the discovery of biologics for the treatment of rheumatoid arthritis 20 years ago. Experts are predicting that drugs used in migraine are going to top the market sales in the pharmaceutical industry.
Fox News cited this report saying biologics was once a blockbuster drug to treat rheumatoid arthritis and it would appear that drugs to prevent migraine could get the same popularity rate these days. Pharmaceutical companies like Amgen Inc. and Alder Biopharmaceuticals are now racing to get their product out on the market.
There are an estimated 40 million people who are suffering from migraine and that is 1 in every 8 people in America. The number is high yet the solution is low, which is why pharmaceutical companies are about to take advantage of this demand this coming 2017. Based on an interview with Reuters, analyst Charles Duncan of Piper Jaffray said that migraine these days is somewhat similar to rheumatoid arthritis before when it affects a lot of people, yet it is often underdiagnosed and under-treated.
As of the moment, people suffering from migraine are resorting to drugs that are anti-depressants or medicines for hypertension. Botox is even used but there was little success in its results.
Analysts like Duncan are expecting the market for migraine drugs to go huge in 2025 that it would reach up to $10 billion in sales. It is not unlikely to occur since it already went to $3 billion last year in America and some areas in Europe and Japan based on the data sent by Decision Resources Group, a healthcare data provider.
Soon as these migraine drugs are approved, there is a chance that sales would at least hit $1 billion due to the lack of efficacy of other treatment following a huge number of people affected by it.
